GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -82.05 | 0.37 | 2.08 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -100.00 | -0.80 | 0.00 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -100.00 | -0.56 | 0.00 | |
| Cash | 100.00 | 0.07 | 0.00 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -100.00 | -0.22 | 0.00 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | n.A. | -1.25 | n.A. | |
| ROE | n.A. | 0.57 | n.A. | |
| ROIC | n.A. | 1.11 | n.A. | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of GNRO.PA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of GNRO.PA is permitted for members.
6
Leverage & Liquidity